Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University Hospital

NCT07302100 | Recruiting

• 1 other identifier: 9485
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Neuroendocrine tumors represent a heterogeneous group of tumors, of which gastrointestinal (gastroenteropancreatic) NETs are the most frequent. Therapeutic management involves several approaches: control of any secretory syndrome and tumor control. Surgery is the first-line treatment for localized stages. When there is distant metastasis, various systemic treatments can be combined or administered sequentially (somatostatin analogs, everolimus, sunitinib, radioablation, targeted internal radiotherapy, cytotoxic chemotherapy). Gastrointestinal NETs are most often well-differentiated and slow-growing tumors with a median overall survival of up to 9 years (all sites combined), making comprehensive management of these patients all the more important. In the context of cancer management, malnutrition has been shown to be associated with a poorer prognosis. Similarly, addressing malnutrition and improving nutritional parameters have been associated with improved prognosis. The impact of nutritional status in patients with slow-growing tumors such as gastrointestinal neuroendocrine tumors (NETs) is less well understood but could be a modifiable factor for improving quality of life and treatment efficacy. The research hypothesis is that nutritional status is associated with the prognosis of patients with gastrointestinal NETs.

Conditions

Gastroenteropancreatic Neuroendocrine Tumor

Keywords

Gastroenteropancreatic Neuroendocrine Tumor; Neuroendocrine tumors; Gastroenteropancreatic; Gastrointestinal

Outcome Measures

Primary Outcomes (1)

• Establish a proportion of patients with malnutrition

  The proportion of patients with malnutrition based on weight loss, compared to usual weight before the onset of illness, is distributed as follows: * weight loss ≥ 5% in 1 month or * weight loss ≥ 10% in 6 months

  Up to 12 months

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults aged 18 to 70 years being monitored for a digestive neuroendocrine tumor (gastric, pancreatic, intestinal), diagnosed between January 1, 2000, and November 30, 2024

You may qualify if:

• Adults aged 18 to 70 years
• Patients being monitored for a digestive neuroendocrine tumor (gastric, pancreatic, intestinal), diagnosed between January 1, 2000, and November 30, 2024

You may not qualify if:

• \- Tumor reclassified as non-neuroendocrine by histopathology

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service d'Endocrinologie, Diabétologie, Nutrition - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Gastro-enteropancreatic neuroendocrine tumor; Neuroendocrine Tumors

Condition Hierarchy (Ancestors)

Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue

Central Study Contacts

Philippe BALTZINGER, MD

CONTACT

33 3 88 12 75 82; philippe.baltzinger@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 11, 2025
• First Posted: December 24, 2025
• Study Start: December 12, 2024
• Primary Completion: February 1, 2026
• Study Completion: February 1, 2026
• Last Updated: December 24, 2025

Record last verified: 2025-12

Locations

FR (1)